Shantha Biotech launches brain fever vaccine
By siliconindia staff writer   |   Monday, 18 April 2005, 19:30 IST
Printer Print Email Email
HYDERABAD:Shantha Biotechnics, has introduced JENCEVAC, a vaccine for combating Japanese Encephalitis (commonly known as Brain Fever) in the domestic market. Shantha Biotech has formed a partnership with Green Cross Vaccine Corporation, Korea for distribution and marketing of JENCEVAC in India. Japanese Encephalitis – the most epidemic and viral encephalitis is an inflammation of the brain, which is a reaction of the body's immune system to infection or invasion. The viruses live in animal hosts and mosquitoes that transmit the disease to humans, often leading to permanent mental disability and sometimes death. Commenting on the launch, Dr. Varaprasad Reddy, Managing Director of Shantha Biotechnics, said “Jencevac is produced using the inactivated Nakayama strain known for its good propagation characteristics and its strength to provide cross-protection against other JE viral strains. With Jencevac, Shantha reiterates its dedication of providing excellent human healthcare products at affordable prices matched with good quality. JE vaccine is yet another step we’ve taken forward for fulfilling our mission of creating a healthy and ailment-free society.”

siliconindia